NCT07850518Completed
Magnetic Mitohormesis (MM) Treatment in Stroke Rehabilitation.
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
Although sarcopenia is commonly seen in stroke patients with a prevalence rate of 42%, relevant research studies are more in geriatric population rather than in stroke patients. Beside conventional functional physiotherapy, improving blood circulation, improving cellular oxygenation and reducing inflammation by MM therapy is supposed to improve muscle atrophy after stroke, thus enhancing the functional recovery. The investigators are not investigating the direct effect of MM therapy on muscle mass in the current study, but are looking at the function outcomes and changes in quality of life of patients after MM therapy, which is more relevant to the clinical practice in stroke recovery. Based on literature review and previous studies, stroke patients might benefit from MM therapy by enhancing the outcomes in functional mobility and measures of quality of life, so the purpose of this study is to investigate if MM treatment could boost the functional recovery and muscle strength on top of the effects from the conventional physiotherapy. The findings of this study might improve the medical knowledge on how MM therapy could affect clinical function outcome in post-stroke rehabilitation and provide alternative method to enhance motor recovery.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 24 Jun 2024
- Start date
- 20 Mar 2024
- Primary completion date
- 1 Mar 2026
- Lead sponsor
- QuantumTX Pte Ltd
- Diseases
- Stroke
- NCT number
- NCT07850518
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 20 Mar 2024 to the primary completion date, 1 Mar 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to PEMF therapy, which include electronic implants (e.g., pacemaker, implantable cardioverter defibrillator, cochlear implants)
- Simultaneously receiving standard care
Other illness
- History of neurological disorder (e.g Seizure, Myasthenia Gravis, Multiple Sclerosis and Myopathies) other than stroke
Other
- Pregnant and lactating women
Who the study is looking for
- Adult age 30 - 70 years
- Diagnosis of stroke(s), with most recent stroke at least 10 weeks prior to study participation
- Functional Ambulation Categories (FAC): 2 to 3
- Normal cognition with Montreal Cognitive Assessment (MOCA) score 21
- Intact language skills to comprehend and follow directions as per Investigator's assessment.
- Individuals must agree to comply with all study visits and procedures.
- Individuals must freely provide consent to study participation.
Age in the registry: 30 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stroke Support Station (S3) - Enabling Village Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| Stroke Support Station (S3) - Jurong Point Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.